{"id":"placebo-tablet-of-rivaroxaban","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Gastrointestinal bleeding"},{"rate":"1-5%","effect":"Hemorrhage"},{"rate":"1-5%","effect":"Anemia"},{"rate":"1-5%","effect":"Thrombocytopenia"},{"rate":"1% or less","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by selectively inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots. This mechanism of action is specific to the coagulation pathway and does not affect other physiological processes.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:38.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Deep vein thrombosis"},{"name":"Pulmonary embolism"},{"name":"Atrial fibrillation for stroke prevention"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT05009862","phase":"PHASE4","title":"The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-19","conditions":"Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT06396858","phase":"PHASE4","title":"Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-07","conditions":"Ischemic Stroke","enrollment":4500},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT04263038","phase":"PHASE4","title":"Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","status":"RECRUITING","sponsor":"Drahomir Aujesky","startDate":"2020-05-15","conditions":"Pulmonary Embolism, Embolism, Embolism and Thrombosis","enrollment":276},{"nctId":"NCT06611319","phase":"PHASE3","title":"ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty","status":"RECRUITING","sponsor":"Prof. Stavros Konstantinides, MD","startDate":"2024-11-26","conditions":"Hip Arthroplasty, Total, Prevention of Venous Thromboembolism","enrollment":2932},{"nctId":"NCT06372483","phase":"PHASE1","title":"Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-02-21","conditions":"Coagulation Disorder","enrollment":40},{"nctId":"NCT04273516","phase":"PHASE2, PHASE3","title":"Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2020-08-22","conditions":"Stroke, Prevention","enrollment":42},{"nctId":"NCT04508023","phase":"PHASE3","title":"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-08-13","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":1284},{"nctId":"NCT01776424","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-28","conditions":"Prevention & Control","enrollment":27395},{"nctId":"NCT03055026","phase":"PHASE3","title":"Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.","status":"COMPLETED","sponsor":"Fadoi Foundation, Italy","startDate":"2017-05-03","conditions":"Prevention of Venous Thromboembolism","enrollment":582},{"nctId":"NCT04504032","phase":"PHASE2","title":"A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2020-09-02","conditions":"COVID-19","enrollment":497},{"nctId":"NCT02504216","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-18","conditions":"Peripheral Artery Disease","enrollment":6564},{"nctId":"NCT02111564","phase":"PHASE3","title":"A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-07","conditions":"Heart Failure, Respiratory Insufficiency, Stroke Acute","enrollment":12024},{"nctId":"NCT02555878","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-11","conditions":"Neoplasms","enrollment":841},{"nctId":"NCT01877915","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-10","conditions":"Heart Failure, Coronary Artery Disease","enrollment":5081},{"nctId":"NCT02313909","phase":"PHASE3","title":"Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-12-23","conditions":"Stroke","enrollment":7213},{"nctId":"NCT02401594","phase":"PHASE3","title":"PROphylaxis in NOn Major Orthopaedic Surgery","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-12-08","conditions":"Non-major Orthopaedic Surgery","enrollment":3608},{"nctId":"NCT02123524","phase":"PHASE3","title":"Rivaroxaban Anticoagulation for Superficial Vein Thrombosis","status":"COMPLETED","sponsor":"McMaster University","startDate":"2014-11-11","conditions":"Symptomatic Superficial Vein Thrombosis","enrollment":85},{"nctId":"NCT00571649","phase":"PHASE3","title":"Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Venous Thromboembolism","enrollment":8101},{"nctId":"NCT00494871","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-06","conditions":"Atrial Fibrillation","enrollment":1280},{"nctId":"NCT01954238","phase":"PHASE1","title":"A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":46},{"nctId":"NCT00439725","phase":"PHASE3","title":"Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-02","conditions":"Venous Thromboembolism","enrollment":1197},{"nctId":"NCT00362232","phase":"PHASE3","title":"Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-06","conditions":"Venous Thromboembolism","enrollment":3148},{"nctId":"NCT00396786","phase":"PHASE2","title":"Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-11","conditions":"Venous Thromboembolism","enrollment":877},{"nctId":"NCT00809965","phase":"PHASE3","title":"An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia","enrollment":15526},{"nctId":"NCT00403767","phase":"PHASE3","title":"An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-12","conditions":"Atrial Fibrillation, Stroke, Embolism","enrollment":14269},{"nctId":"NCT00402597","phase":"PHASE2","title":"Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Acute Coronary Syndrome","enrollment":3490}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo: tablet of Rivaroxaban","genericName":"Placebo: tablet of Rivaroxaban","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade. Used for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}